ティーセルヌーヴォー㈱
1 known investors
T-Cell Nouveau develops T-cell based immunotherapies, including γδT cell and GD2 GITRL CAR programs, aimed at treating cancer. The company operates in the biotech and cell therapy space.
Investors · 1
Frequently asked questions
- What does ティーセルヌーヴォー㈱ do?
- T-Cell Nouveau develops T-cell based immunotherapies, including γδT cell and GD2 GITRL CAR programs, aimed at treating cancer. The company operates in the biotech and cell therapy space.
- Who are ティーセルヌーヴォー㈱'s investors?
- ティーセルヌーヴォー㈱'s investors include DBJ Capital.